AR and prostate carcinoma: Although first‐line treatment with ADT and second‐generation AR antagonists, such as enzalutamide and abiraterone, are used to inhibit AR signaling in patients with prostate cancer, AR activity persists due to direct alterations to the signaling axis.[32] Therefore, the use of AR degraders for targeted protein degradation has significant potential as a crucial therapeutic approach to address the needs of patients with CRPC.